Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Astellas Pharma Inc.    4503   JP3942400007


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma : Supports Recommendations of Task Force on Climate-related Financial Disclosures

12/18/2020 | 05:29am EST

TOKYO - Astellas Pharma Inc. expressed its support for the recommendation of the Task Force on Climate-related Financial Disclosures1 (TCFD), established by the Financial Stability Board (FSB).

Based on the recommendation, Astellas will analyze climate-related risks and opportunities, and proactively disclose of information on climate change measures from FY 2021 around the four thematic areas of Governance, Strategy, Risk Management, and Metrics and Targets.

As a company dedicated to improving the health of people around the world, Astellas is conducting its business activities in harmony with the global environment to contribute to the development of a sustainable society. Recognizing that addressing climate change mitigation measures is an important corporate focus, Astellas is working proactively to reduce greenhouse gas (GHG) emissions. As part of its efforts, the company has already purchased electricity generated by renewable energy sources at some of R&D and manufacturing facilities, installed a wind power mill and a biomass boiler, and the sales force use hybrid vehicles. These efforts allow for the company to reduce its GHG emissions (Scope 1 and 2) 2 by 18.5% from the FY 2015 baseline. Astellas discloses its measures to address climate change on the company's website3.

In November 2018, Astellas' GHG reduction targets were approved by the Science Based Targets initiative (SBT / Reduction Targets Aligned with Scientific Knowledge), which encourages companies to set reduction targets in line with the Paris Agreement. In addition, Astellas plans to position Sustainability as one of its initiatives of Corporate Strategic Plan, which will be launched in FY 2021, from the perspective of sustainable enhancement of corporate value.

Astellas will continue to identify and implement measures to help solve global environmental issues, such as climate change, and make a meaningful contribution to people's health all over the world by harmonizing its business activities with the global environment.

About Astellas

Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+ healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients.

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice


Tel: +81-3-3244-3201

Fax: +81-3-5201-7473

(C) 2020 Electronic News Publishing, source ENP Newswire

09:25aASTELLAS PHARMA  : Notice Regarding Continuation of the Performance-linked Stock..
02/26ASTELLAS PHARMA  : Notice Regarding Continuation of the Performance-linked Stock..
02/24PRESS RELEASE  : Creative Balloons closes EUR15 million growth financing and app..
02/22ASTELLAS PHARMA  : Announces Positive Topline Results from Two Phase 3 Pivotal G..
02/19ASTELLAS PHARMA  : and Seagen Announce Submission of Two Supplemental Biologics ..
02/15SEAGEN  : and Astellas Announce Phase 3 Trial Results Demonstrating Survival Adv..
02/15ASTELLAS PHARMA  : and Seagen Announce Presentation of Results from PADCEV Pivot..
02/09Japan shares edge higher driven by Honda's upbeat earnings outlook
02/04ASTELLAS PHARMA  : XOSPATA Receives Conditional Approval by China's National Med..
02/04ASTELLAS PHARMA  : Announces Management Structure
More news
Sales 2021 1 258 B 11 780 M 11 780 M
Net income 2021 176 B 1 648 M 1 648 M
Net cash 2021 440 B 4 117 M 4 117 M
P/E ratio 2021 17,7x
Yield 2021 2,46%
Capitalization 3 177 B 29 797 M 29 751 M
EV / Sales 2021 2,18x
EV / Sales 2022 2,02x
Nbr of Employees 15 883
Free-Float 99,2%
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 2 261,54 JPY
Last Close Price 1 710,50 JPY
Spread / Highest target 110%
Spread / Average Target 32,2%
Spread / Lowest Target -3,54%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Fumiaki Sakurai Head-Business Administration & Compliance
Mamoru Sekiyama Independent Outside Director
Keiko Yamagami Independent Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON0.69%416 541
ROCHE HOLDING AG-3.58%280 845
NOVARTIS AG-6.53%194 250
ABBVIE INC.0.55%190 256
PFIZER INC.-9.02%186 852